Stimulating nerve repair after spinal cord injury
News
Novago is expanding it’s research team
Zurich, Switzerland (25.11.2025).
We are looking for a highly skilled scientist to join our research team. If this is you please check out the job ad and apply immediately.
Who we are
NovaGo Therapeutics is a Swiss biotech company focused on human antibody therapeutics targeting nerve growth and regeneration to enhance functional recovery following spinal cord injury.
Spinal Cord Injury
Spinal cord injury is a devastating neurological disorder caused by damage of nerve cells in the spinal cord. It affects people’s lives through loss of sensation and motor paralysis below the site of the injury. Functional recovery is often hindered by the limited capacity of the human central system to self-repair nerve damage.
Stimulating nerve repair
NovaGo develops a human therapeutic antibody to enhance nerve growth and regeneration by blocking Nogo-A receptor, a potent inhibitor of nerve growth. NovaGo’s therapeutic antibody candidates have shown to enhance nerve repair and functional recovery in preclinical models. Phase 1b clinical trials for the treatment of spinal cord injury are expected to start in 2024.